Page last updated: 2024-08-24

gemcitabine and 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin

gemcitabine has been researched along with 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dibbern, JL; Ghadban, T; Güngör, C; Izbicki, JR; Miro, JT; Reeh, M; Tsui, TY; Vashist, YK; Wellner, U	1

Other Studies

1 other study(ies) available for gemcitabine and 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin

Article	Year
HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer. Apoptosis : an international journal on programmed cell death, 2017, Volume: 22, Issue:3 Topics: Adenocarcinoma; Apoptosis; Benzoquinones; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lactams, Macrocyclic; Molecular Targeted Therapy; Neoplasm Proteins; Pancreatic Neoplasms; Recurrence	2017

Article

Year

HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer.

Apoptosis : an international journal on programmed cell death, 2017, Volume: 22, Issue:3

Topics: Adenocarcinoma; Apoptosis; Benzoquinones; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lactams, Macrocyclic; Molecular Targeted Therapy; Neoplasm Proteins; Pancreatic Neoplasms; Recurrence

2017